Evidence map›Paper›PMID 40121229›Full record

ArticleCell death & disease2025

LL37 complexed to double-stranded RNA induces RIG-I-like receptor signalling and Gasdermin E activation facilitating IL-36γ release from keratinocytes.

Jennifer Keller, Judit Danis, Isabella Krehl, Eleftheria Girousi, Takashi K Satoh, Barbara Meier-Schiesser, Lajos Kemény, Márta Széll, W Wei-Lynn Wong, Steve Pascolo and 3 more

Abstract read
In one paragraph

Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jennifer KellerDepartment of Dermatology, University Hospital Zürich (USZ), University of Zürich (UZH), Raemistrasse 100, 8091, Zürich, Switzerland.ORCID http://orcid.org/0009-0006-0417-4237
Judit DanisDepartment of Dermatology, University Hospital Zürich (USZ), University of Zürich (UZH), Raemistrasse 100, 8091, Zürich, Switzerland.ORCID http://orcid.org/0000-0002-0270-5309
Isabella KrehlDepartment of Dermatology, University Hospital Zürich (USZ), University of Zürich (UZH), Raemistrasse 100, 8091, Zürich, Switzerland.ORCID http://orcid.org/0009-0002-2370-8186
Eleftheria GirousiDepartment of Dermatology, University Hospital Zürich (USZ), University of Zürich (UZH), Raemistrasse 100, 8091, Zürich, Switzerland.
Takashi K SatohDepartment of Dermatology and Allergy, University Hospital, LMU Münich, Germany.ORCID http://orcid.org/0000-0002-6064-9253
Barbara Meier-SchiesserDepartment of Dermatology, University Hospital Zürich (USZ), University of Zürich (UZH), Raemistrasse 100, 8091, Zürich, Switzerland.ORCID http://orcid.org/0000-0003-2807-5066
Lajos KeményDepartment of Immunology, University of Szeged, Szeged, Hungary.ORCID http://orcid.org/0000-0002-2119-9501
Márta SzéllDepartment of Medical Genetics, University of Szeged, Szeged, Hungary.ORCID http://orcid.org/0000-0002-0730-714X
W Wei-Lynn WongDepartment of Molecular Life Sciences, University of Zürich, Winterthurerstrasse 190, 8057, Zürich, Switzerland.ORCID http://orcid.org/0000-0003-3155-1211
Steve PascoloDepartment of Dermatology, University Hospital Zürich (USZ), University of Zürich (UZH), Raemistrasse 100, 8091, Zürich, Switzerland.ORCID http://orcid.org/0000-0003-2946-5576
Lars E FrenchDepartment of Dermatology and Allergy, University Hospital, LMU Münich, Germany.ORCID http://orcid.org/0000-0002-4629-1486
Thomas M KündigDepartment of Dermatology, University Hospital Zürich (USZ), University of Zürich (UZH), Raemistrasse 100, 8091, Zürich, Switzerland.ORCID http://orcid.org/0000-0003-3863-8766
Mark MellettDepartment of Dermatology, University Hospital Zürich (USZ), University of Zürich (UZH), Raemistrasse 100, 8091, Zürich, Switzerland. mark.mellett@usz.ch.ORCID http://orcid.org/0000-0002-6315-167X

Funding

EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) 965135LEO Pharma Research Foundation LF-OC-22-000968Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) 310030_201242Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) 4078PO_198321Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation) IZSEZ0_185113
6 · The paper itself

Abstract

The Interleukin-36 (IL-36) cytokine family have emerged as important players in mounting an inflammatory response at epithelial barriers and tailoring appropriate adaptive immune responses. As members of the Interleukin-1 superfamily, IL-36 cytokines lack a signal peptide for conventional secretion and require extracellular proteolysis to generate bioactive cytokines. Although the IL-36 family plays an important role in the pathogenesis of plaque and pustular psoriasis, little is known about the release mechanisms of these cytokines from keratinocytes and the physiological stimuli involved. Nucleic acid released from damaged or dying keratinocytes initiates early inflammatory signals that result in the breaking of tolerance associated with psoriasis pathogenesis onset. Cathelicidin peptide, LL37 binds to DNA or double-stranded RNA (dsRNA) and activates a type I Interferon responses in plasmacytoid dendritic cells and keratinocytes. Here, we demonstrate that LL37 binds to dsRNA and induces IL-36γ release from human primary keratinocytes. LL37/dsRNA complexes activate RIG-I-like Receptor signalling, resulting in Caspase-3 and Gasdermin E (GSDME) cleavage. Subsequent GSDME pore formation facilitates IL-36γ release. This response is magnified by priming with psoriasis-associated cytokines, IL-17A and IFNγ. IL-36γ release in this manner is largely independent of cell death in primary keratinocytes and lacked extracellular proteolysis of IL-36γ. Conversely, transfection of keratinocytes directly with dsRNA synthetic analogue, Poly(I:C) induces NLRP1 inflammasome activation, which facilitates IL-36γ expression and release in a GSDMD-dependent manner. Inflammasome-associated cell death also enables extracellular processing of IL-36γ by the release of keratinocyte-derived proteases. These data highlight the distinct responses triggered by dsRNA sensors in keratinocytes. Depending on the inflammatory context and magnitude of the exogenous threat, keratinocytes will release IL-36γ coupled with cell death and extracellular cleavage or release the inactive pro-form, which requires subsequent processing by neutrophil proteases to unleash full biological activity, as occurring in psoriatic skin. Cytoplasmic sensing of dsRNA in keratinocytes mediates IL-36γ release via caspase activity and GSDM pore formation Keratinocytes release IL-36γ upon stimulation with intracellular dsRNA alone or complexed to the psoriasis-associated cathelicidin anti-microbial peptide LL37. Left: Transfected dsRNA triggers NLRP1 inflammasome assembly and IL-1β release, which can enhance IL-36γ expression, resulting in IL-36γ release and extracellular cleavage by released proteases. Right: LL37/dsRNA complexes activate a MDA5-MAVS pathway facilitating the release of IL-36γ through Caspase-3 activation and GSDME pore formation.

Indexed as

Antimicrobial Cationic PeptidesCathelicidinsDEAD Box Protein 58Interleukin-1KeratinocytesNeoplasm ProteinsRNA, Double-StrandedCaspase 3GasderminsHumansInflammasomesPhosphate-Binding ProteinsPsoriasisReceptors, ImmunologicSignal TransductionAntimicrobial Cationic PeptidesCaspase 3CathelicidinsDEAD Box Protein 58GasderminsGSDMD protein, humanIL36G protein, humanInflammasomesInterleukin-1Neoplasm ProteinsPhosphate-Binding ProteinsReceptors, ImmunologicRIGI protein, humanRNA, Double-Stranded

Identifiers

PMID40121229
PMCPMC11929817

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.